Filing Details
- Accession Number:
- 0001415889-22-011237
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-11-09 16:16:08
- Reporting Period:
- 2022-11-07
- Accepted Time:
- 2022-11-09 16:16:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1730430 | Kiniksa Pharmaceuticals Ltd. | KNSA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1741533 | F. John Paolini | C/O Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton D0 HM 11 | Chief Medical Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Share | Acquisiton | 2022-11-07 | 28,357 | $1.86 | 64,692 | No | 4 | M | Direct | |
Class A Common Share | Disposition | 2022-11-07 | 28,357 | $15.18 | 36,335 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Class A Common Share | Share Option | Disposition | 2022-11-07 | 28,357 | $0.00 | 28,357 | $1.86 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
169,217 | 2026-09-13 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022.
- This transaction was executed in multiple trades through a broker-dealer at prices ranging from $15.00 to $15.45. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- The option is fully vested and exercisable.